You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Zepbound® (tirzepatide) available as an oral formulation?
Tirzepatide is not available in pill form for oral administration. Tirzepatide is an injectable medicine for subcutaneous use.
Boxed Warning
See important safety information, including boxed warning, in the attached prescribing information.
Tirzepatide Formulation
Tirzepatide is not available in pill form for oral administration.1
Tirzepatide is an injectable medicine for subcutaneous use. It contains tirzepatide, a once weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.1
The molecular weight of tirzepatide is 4813.53 daltons.1 Generally, medicines with a molecular weight greater than 500 daltons are not absorbed orally.
Tirzepatide injection is a clear, colorless to slightly yellow, sterile solution.1
Enclosed Prescribing Information
Reference
1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: September 23, 2025